Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)’s stock price traded up 4.7% during mid-day trading on Monday . The stock traded as high as $5.78 and last traded at $6.03, 65,791 shares traded hands during mid-day trading. A decline of 95% from the average session volume of 1,426,958 shares. The stock had previously closed at $5.76.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Wednesday, July 31st. ValuEngine cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. Cantor Fitzgerald upped their target price on Catalyst Pharmaceuticals from $10.00 to $12.00 in a report on Thursday, August 8th. BidaskClub upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Finally, HC Wainwright set a $9.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, May 14th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $8.54.

The company has a current ratio of 5.09, a quick ratio of 5.07 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $4.63 and a 200-day simple moving average of $4.05. The company has a market capitalization of $551.70 million, a PE ratio of -18.12 and a beta of 2.60.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. The business had revenue of $28.84 million for the quarter, compared to analysts’ expectations of $17.99 million. The business’s revenue for the quarter was up 2883900.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) earnings per share. On average, equities analysts predict that Catalyst Pharmaceuticals Inc will post 0.34 EPS for the current fiscal year.

In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany purchased 25,000 shares of the stock in a transaction dated Tuesday, June 11th. The stock was acquired at an average cost of $3.23 per share, for a total transaction of $80,750.00. Following the acquisition, the chief executive officer now owns 4,762,693 shares in the company, valued at approximately $15,383,498.39. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 10.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA purchased a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth $102,000. Bank of New York Mellon Corp grew its holdings in shares of Catalyst Pharmaceuticals by 8.3% during the 4th quarter. Bank of New York Mellon Corp now owns 334,078 shares of the biopharmaceutical company’s stock worth $641,000 after purchasing an additional 25,498 shares during the period. Kennedy Capital Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals during the 1st quarter worth $5,099,000. Metropolitan Life Insurance Co. NY grew its holdings in shares of Catalyst Pharmaceuticals by 291.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 20,297 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 1,063,768 shares of the biopharmaceutical company’s stock worth $2,042,000 after purchasing an additional 101,584 shares during the period. Institutional investors and hedge funds own 60.98% of the company’s stock.

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Read More: What is meant by holder of record?

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.